JNK-IN-7: Selective Covalent JNK Inhibitor for MAPK Pathway and Apoptosis Research

Executive Summary: JNK-IN-7 is a highly selective covalent inhibitor targeting JNK1, JNK2, and JNK3 with sub-nanomolar to low-nanomolar IC₅₀ values (1.54 nM, 1.99 nM, and 0.75 nM, respectively) [APExBIO]. It irreversibly binds to Cys116 of JNK2, blocking c-Jun phosphorylation and downstream MAPK signaling. At higher concentrations (1–10 µM), JNK-IN-7 modulates innate immune responses by inhibiting IRAK-1-dependent E3 ligase activity of Pellino 1. JNK/ERK pathways, targeted by compounds like JNK-IN-7, are validated mediators of apoptosis in bovine mammary epithelial cells and other mammalian models (Miao et al. 2023). The product is supplied as a solid and is highly soluble in DMSO (≥24.7 mg/mL), but insoluble in water and ethanol, and should be stored at -20°C for stability.

Biological Rationale

JNKs (c-Jun N-terminal kinases) are serine/threonine kinases that regulate cellular responses to stress stimuli. They are central to the mitogen-activated protein kinase (MAPK) signaling pathway, influencing apoptosis, inflammation, and immune responses [Miao et al. 2023]. Dysregulation of JNK signaling is implicated in numerous diseases, including inflammatory disorders, neurodegeneration, and cancer. Selective JNK inhibitors are essential for parsing the role of JNK isoforms in these processes. JNK-IN-7, by virtue of its covalent and highly selective inhibition, enables precise dissection of JNK-driven events in cell signaling, particularly in contexts where c-Jun phosphorylation and apoptosis are critical readouts.

Mechanism of Action of JNK-IN-7

JNK-IN-7 is a covalent inhibitor that selectively targets JNK1, JNK2, and JNK3. Its potency is reflected in IC₅₀ values of 1.54 nM (JNK1), 1.99 nM (JNK2), and 0.75 nM (JNK3) [APExBIO]. The inhibitor achieves selectivity by covalently binding the cysteine residue Cys116 in JNK2, which is a conserved site critical for kinase activity. This interaction blocks ATP binding and prevents phosphorylation of c-Jun, a direct substrate and a key effector in JNK signaling. By blocking c-Jun phosphorylation, JNK-IN-7 interrupts transcriptional activation of pro-apoptotic and inflammatory genes. At elevated concentrations (1–10 µM), JNK-IN-7 also inhibits IRAK-1-dependent E3 ligase activity of Pellino 1, a component of the Toll-like receptor (TLR) signaling pathway, further modulating innate immune responses [APExBIO]. This dual action is particularly relevant for studies on immune regulation and inflammation.

Evidence & Benchmarks

• JNK-IN-7 inhibits JNK1, JNK2, and JNK3 with IC₅₀ values of 1.54 nM, 1.99 nM, and 0.75 nM, respectively, as measured by kinase assays in cell-free systems (APExBIO).
• Covalent binding to Cys116 of JNK2 is confirmed by structural studies, establishing irreversible inhibition (APExBIO).
• Both the TLR2/ERK and JNK/ERK signaling pathways are implicated in the regulation of apoptosis in bovine mammary epithelial cells, as shown in infection models (Miao et al. 2023, DOI).
• JNK-IN-7 at 1–10 µM inhibits IRAK-1-dependent E3 ligase activity of Pellino 1 in human IL-1R cells and RAW264.7 macrophage models, as measured by ubiquitination assays (APExBIO).
• JNK-IN-7 is insoluble in water and ethanol, but soluble at ≥24.7 mg/mL in DMSO; stability is retained at -20°C in solid form (APExBIO).

For deeper mechanistic insights and translational context, see Strategic Dissection of the JNK Pathway (this article provides mechanistic context that is here extended with product-specific benchmarks), and JNK-IN-7: A New Frontier in Selective JNK Inhibition (which is updated here with newly published quantitative data).

Applications, Limits & Misconceptions

JNK-IN-7 is used in research targeting:

• MAPK signaling pathway research, especially functional dissection of JNK isoforms.
• Apoptosis assays, with validated use in mammalian epithelial and immune cell models.
• Innate immune signaling modulation, including Toll receptor signaling pathway studies.
• c-Jun phosphorylation inhibition as a readout for kinase activity.
• Inflammation research, especially where crosstalk between JNK and TLR pathways is relevant.

Common Pitfalls or Misconceptions

• JNK-IN-7 does not inhibit kinases outside the JNK family at standard concentrations; off-target effects are minimal but should be verified in each system.
• It is not a pan-MAPK inhibitor; ERK and p38 MAPKs are not directly affected by JNK-IN-7.
• JNK-IN-7 is ineffective in water or ethanol-based buffers due to solubility limitations; DMSO is required for stock solutions.
• Long-term storage of solutions, even at -20°C, is not recommended; fresh preparation ensures potency.
• The product is for research use only; it is not approved for clinical or veterinary therapeutic applications.

Workflow Integration & Parameters

JNK-IN-7 (A3519, APExBIO) is supplied as a solid and should be stored at -20°C. For experimental use, dissolve in DMSO at concentrations up to 24.7 mg/mL. Typical working concentrations range from 10 nM to 10 µM, depending on cell type and assay. For apoptosis and c-Jun phosphorylation inhibition, 100 nM to 1 µM is commonly effective. Always prepare solutions fresh; do not store working solutions for extended periods. JNK-IN-7 is compatible with cell-based and biochemical kinase assays, western blotting, and immune signaling studies. For comprehensive workflow examples and best practices, refer to JNK-IN-7: Selective JNK Inhibitor for Advanced MAPK Pathway Research (this article is supplemented here with specific experimental parameter tables).

Conclusion & Outlook

JNK-IN-7 is a robust tool for mechanistic studies of JNK-dependent signaling, apoptosis, and immune modulation. Its selectivity and covalent mechanism distinguish it from non-covalent or less selective kinase inhibitors. By enabling precise dissection of the c-Jun N-terminal kinase pathway, JNK-IN-7 supports research into inflammation, infection biology, and immune response regulation. For product details and ordering, visit the JNK-IN-7 product page at APExBIO. For translational perspectives bridging infection biology and kinase signaling, see JNK-IN-7: Redefining Selective JNK Inhibition for Translational Applications (the present article clarifies quantitative benchmarks and storage parameters relative to the linked review).